Drug and pharmaceutical recalls
709 federal recalls in the last 12 months. Federal recalls for prescription drugs, OTC medications, supplements, and pharmaceuticals. Sourced from the FDA and translated into plain English.
- 2026-04-15FDA-DrugTeva Pharmaceuticals USA, IncClass IIStop using Teva Isotretinoin 30 mg capsules
Teva Pharmaceuticals is recalling specific lots of Isotretinoin 30 mg capsules because some capsules may contain too much active ingredient (superpotent) while others may contain too little (subpotent). This inconsistency could affect how well the medication works or increase the risk of side effects.
- 2026-04-15FDA-DrugViatris, Inc.Class IICheck your Xanax XR 3 mg prescription bottle
Viatris is recalling one lot of Xanax XR (alprazolam) 3 mg extended-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication properly in your body. This affects only lot #8177156 with an expiration date of 02/28/2027, distributed nationwide. No injuries have been reported.
- 2026-04-15FDA-DrugPreferred Pharmaceuticals, Inc.Class IIStop using Preferred Pharmaceuticals Artificial Tears
Preferred Pharmaceuticals' Artificial Tears Lubricant Eye Drops in 0.5 oz bottles may not be sterile due to a manufacturing issue. The FDA is recalling specific lots because sterility cannot be assured. No injuries have been reported.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IIStop using Fagron Vancomycin HCL IV bags
Fagron Compounding Services is recalling specific lots of Vancomycin HCL injections due to two safety concerns: the bags may not be sterile, and a blue plastic part on the administration port could detach during use. The recall affects over 11,600 bags distributed nationwide.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IIVancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5085-01
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IIVancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5083-01
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IIStop using Fagron norepinephrine injection
Fagron Compounding Services is recalling norepinephrine bitartrate injection due to two issues: the sterility of the product cannot be assured, and a blue plastic part on the administration port may detach during use. This medication is used in hospitals and medical facilities to treat critical conditions. Six specific lots distributed nationwide are affected.
- 2026-04-15FDA-DrugFagron Compounding ServicesClass IIDo not use Fagron norepinephrine injection
Fagron Compounding Services is recalling specific lots of norepinephrine bitartrate injection due to two concerns: the product may not be sterile, and a blue plastic piece on the administration port could detach during use. This medication is used in hospitals and clinical settings to support blood pressure in critically ill patients.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi dextrose injection
Fresenius Kabi USA is recalling a specific batch of 5% Dextrose Injection due to concerns that the product may not meet sterility standards. This injectable solution is used in medical settings to deliver fluids and glucose to patients. The affected batch (6402165, expiring 05/30/2028) was distributed nationwide.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIDo not use Fresenius Kabi dextrose injection
Fresenius Kabi is recalling specific batches of 5% Dextrose Injection because the company cannot guarantee the product is sterile. This intravenous solution is used in hospitals and medical settings. The affected batches have expiration dates of February 28, 2027.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi dextrose injection
Fresenius Kabi is recalling a specific batch of 5% Dextrose Injection due to lack of assurance of sterility. The affected product is in 50 mL freeflex bags. This intravenous medication was distributed nationwide, including Alaska and Puerto Rico.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi sodium chloride injection
Fresenius Kabi USA is recalling a specific batch of 0.9% Sodium Chloride Injection (a sterile saline solution used in medical settings) because the manufacturer cannot guarantee it remained sterile during production. The affected batch (24EU10010) was distributed nationwide, including Alaska and Puerto Rico.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% sodium chloride injection (saline) in 1,000 mL freeflex bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline solution) used in medical settings because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide. No injuries have been reported so far.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass II0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL in a Single Dose freeflex bag, Rx only, BD Becton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417, Distributed by BD, Manufactured by: Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Sale NDC Number: 17271-701-05.
Lack of Assurance of Sterility
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIDo not use Fresenius Kabi saline injection
Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (a sterile saline solution) because the manufacturer cannot guarantee the product is free from contamination. The affected batches were distributed nationwide, including Alaska and Puerto Rico, between now and June 2027.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi USA is recalling specific batches of 0.9% Sodium Chloride Injection (saline) because the manufacturer cannot confirm the product is sterile. Sterility is critical for injectable medications. The affected batches have expiration dates of October 31, 2026, or November 30, 2026.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi sodium chloride injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection due to a lack of assurance that the product is sterile. This injectable solution is used in medical settings and could pose a risk if contaminated. No injuries have been reported to date.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi USA is recalling multiple batches of 0.9% Sodium Chloride Injection (saline solution) used for medical purposes because the manufacturer cannot guarantee the product is sterile. The affected batches were distributed nationwide, Alaska, and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection (saline) in 100 mL bags due to lack of assurance of sterility. The affected batches were distributed nationwide, including Alaska and Puerto Rico. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling specific batches of 0.9% Sodium Chloride Injection because the manufacturer cannot guarantee these vials are sterile. This injectable medication is used in hospitals and clinical settings. No injuries have been reported.
- 2026-04-15FDA-DrugFresenius Kabi USA, LLCClass IIStop using Fresenius Kabi saline injection
Fresenius Kabi is recalling one batch of 0.45% sodium chloride injection (saline solution) used in hospitals and medical facilities because the manufacturer cannot guarantee the product is sterile. The affected batch is #6402413 with an expiration date of 02/29/2028. No infections or injuries have been reported so far.
- 2026-04-15FDA-DrugCipla USA, Inc.Class IIStop using Cipla Lanreotide Injection
Cipla USA is recalling specific lots of Lanreotide Injection (120 mg) because the manufacturer did not follow proper visual inspection procedures during production. This means the medication may not meet sterility standards and could potentially be contaminated.
- 2026-04-15FDA-DrugCipla USA, Inc.Class IIDo not use Cipla Lanreotide Injection
Cipla USA is recalling specific lots of Lanreotide Injection 120 mg due to concerns about sterility. The FDA found deficiencies in the manufacturer's visual inspection procedures, which could mean some syringes may not be properly sterilized. No injuries have been reported so far.
- 2026-04-08FDA-PRBlaine Labs, IncStop using Blaine Labs wound care gel
Blaine Labs is recalling three lot numbers of Revitaderm and Tridergel wound care gel (1 oz. and 3 oz. bottles/tubes) because they may contain Lysinibacillus fusiformis, a bacterium found in the environment. The affected products were distributed to healthcare providers only, not sold in stores. No injuries have been reported so far.
- 2026-04-08FDA-DrugAmneal Pharmaceuticals, LLCClass IStop using Amneal Magnesium Sulfate IV bags
Some cartons of Amneal Magnesium Sulfate IV bags were mislabeled and contained Tranexamic Acid (a different medication) instead. This mix-up affects lot AH250162 with an expiration date of 8/31/2027. The error was discovered before the product reached patients.
- 2026-04-08FDA-DrugAppco Pharma LLCClass IIStop using recalled prazosin hydrochloride capsules
Appco Pharma LLC is recalling specific lots of prazosin hydrochloride 5mg capsules because they contain higher-than-acceptable levels of a nitrosamine impurity (N-nitroso-prazosin). Nitrosamines are chemical contaminants that may increase health risks with long-term exposure. This is a manufacturing quality issue, not a safety defect in the drug itself.
- 2026-04-08FDA-DrugAppco Pharma LLCClass IIStop using Appco Pharma prazosin capsules
Appco Pharma LLC is recalling specific lots of prazosin hydrochloride 2mg capsules because they contain higher-than-allowed levels of a nitrosamine impurity called N-nitroso-prazosin. Nitrosamines are chemicals that may increase cancer risk with long-term exposure. No injuries have been reported so far.
- 2026-04-08FDA-DrugAppco Pharma LLCClass IIStop taking recalled prazosin capsules
Appco Pharma LLC is recalling prazosin hydrochloride 1mg capsules (100-count bottles) because they may contain higher-than-acceptable levels of a nitrosamine impurity. This impurity was detected during manufacturing quality checks. The recall affects specific lot numbers distributed nationwide.
- 2026-04-08FDA-DrugK.C. Pharmaceuticals, IncClass IIStop using recalled artificial tears eye drops
Multiple brands of artificial tears eye drops made by K.C. Pharmaceuticals have been recalled because the manufacturer cannot confirm the product is sterile. The affected drops are sold under store brands including Leader, Good Sense, Good Neighbor Pharmacy, TopCare, Best Choice, Kroger, Publix, and Quality Choice. No injuries have been reported.
Get notified about new drug recalls
Free weekly digest. We email when a new federal recall in this category — or anything else affecting your household — is published.